The outreach nature of the new recruitment strategy led to the implementation of a multi-step process to ensure enrollment of appropriate participants. First, initial eligibility was determined based on criteria broadly including that a given individual was aged 60 or older, of a target ethnic group, and fluent in English or Spanish. Second, individuals who met these criteria were administered a subset of the SENAS27 (link),28 (link) that required one to two hours to complete. Third, these SENAS results were then used to identify candidates for a clinical evaluation and possible entry into the longitudinal cohort. Goals for selection were to obtain a broad range of cognitive function from normal to demented, with a particular emphasis on mild cognitive impairment. To achieve these goals, all individuals with significant impairment on any one of five SENAS scales measuring episodic memory, language/semantic memory, spatial ability, abstract reasoning, and attention span were identified as potential candidates. Significant impairment was defined as an age-, education-, and language-adjusted SENAS score below the 10th percentile. In addition, a 25% random sample of screened individuals with no significant impairment on these five measures was identified. (Weighted sampling based on test scores was not an effort to establish prevalence rates for MCI or dementia but rather was a recruitment stratification tool used to obtain a cognitively diverse sample.) Fourth, medical history of individuals identified as potential recruits was then reviewed to screen out those who met exclusion criteria that included unstable major medical illness, major primary psychiatric disorder (history of schizophrenia, bipolar disorder, or recurrent major depression), and substance abuse or dependence in the last five years. These criteria are consistent with other research protocols within the UCD ADC. Based on these steps, eligibility for a clinical evaluation was established. Finally, enrollment in longitudinal research was offered to those who completed the clinical evaluation and continued to meet study eligibility criteria. All participants signed informed consent.